Bacterial translocation aggravates CCl₄-induced liver cirrhosis by regulating CD4⁺ T cells in rats

Haiyan Shi¹,²,*, Longxian Lv¹,²,*, Hongcui Cao¹,², Haifeng Lu¹,², Ning Zhou¹,², Jiezuan Yang¹,², Haiyin Jiang¹,², Huihui Dong¹,², Xinjun Hu¹,², Wei Yu¹,², Xiawei Jiang¹,², Beiwen Zheng¹,² & Lanjuan Li¹,²

Bacterial translocation (BT) is thought to play an important role in the development of liver cirrhosis, but the mechanisms have not been fully explored. This study aims to investigate the distribution of Treg (CD3⁺CD4⁺CD25⁺Foxp3⁺), Th17 (CD3⁺CD4⁺IL-17⁺), and Th1 (CD3⁺CD4⁻IFN-γ⁻) cells in the intestinal lamina propria, liver, and blood in cirrhotic rats with and without BT. Cirrhotic rats with BT had lower levels of total protein and albumin, lower albumin/globulin ratio, lower body weight, and higher spleen weight and ascites volumes in comparison to those without BT. We found that BT may cause an increase in Treg cells in the proximal small intestine and decrease of Th17 cells in the whole intestine and blood in cirrhotic rats. It may also aggravate the CCl₄-induced decrease in Th1 cells in the whole intestine, liver, caecum, and blood, and increase the CCl₄-induced increase in Th17 cells in the liver and Tregs in the distal small intestine, colon, and liver. Our data suggest that BT may aggravate liver injury and decrease liver function via an interaction with CD4⁺ T Cells. The results of this study may be helpful for the development of new treatments for liver cirrhosis.

Bacterial translocation (BT) is a phenomenon in which intestinal bacteria or their products cross the intestinal barrier and enter the mesenteric lymph nodes (MLNs) and/or other extraintestinal organs. An increasing amount of evidence indicates that BT is intimately associated with the development of liver cirrhosis and its complications, such as hepatic encephalopathy, hepatopulmonary syndrome, hepatorenal syndrome, and liver failure. Indeed, BT-associated infections and spontaneous peritonitis are major causes of death in patients with liver cirrhosis. Although bacterial overgrowth into the small intestine, intestinal mucosal barrier damage, and increased intestinal permeability have been observed in patients with liver cirrhosis with BT, the mechanisms of interaction between BT and liver cirrhosis had not previously been fully explained.

Several types of intestinal CD4⁺ T cells are critical for host defences against BT. Th17 cells are distributed primarily in the intestinal lamina propria, especially in the small intestine, and are important for maintaining the integrity of the intestinal mucosal barrier and therefore crucial for preventing BT. Treg cells accumulate in the intestine, where they play key roles in gut homeostasis and thereby affect BT. For example, when Tregs are depleted, it can lead to an abnormal expansion of CD4⁺ T cells, resulting in intestinal inflammation. Conversely, when Tregs are enriched, they can suppress other types of T cells, including Th17 and Th1 cells, and may also disrupt gut homeostasis. In liver cirrhosis, some gut disorders have been associated with BT and CD4⁺ T cells; these include overgrown bacteria in the small intestine, a damaged gastrointestinal barrier, increased intestinal permeability, and an altered gut microbiome. However, changes in intestinal CD4⁺ T cells and their interactions with BT have not previously been explored in liver cirrhosis.

In this study, we aimed to investigate differences in the enrichment of CD4⁺ T cells in the blood, liver, and intestines between CCl₄-induced cirrhotic rats with and without BT to explore the relationship and the mechanism of interaction between BT and alterations in CD4⁺ T cells in liver cirrhosis.

¹The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University, Hangzhou, Zhejiang 310003, China. ²The State Key Laboratory for Diagnosis and Treatment of Infectious Disease, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China. These authors contributed equally to this work. Correspondence and requests for materials should be addressed to L.L. (email: ljli@zju.edu.cn)
Results

CCL4-induced cirrhosis increases the incidence of BT. To determine whether cirrhosis affects BT, MLNs were isolated using sterile procedures for bacterial cultures according to the BT diagnostic criteria. As shown in Fig. 1a, the MLNs obtained from 11/23 (47.8%) of the cirrhotic rats produced bacterial isolates in MacConkey, Mueller–Hinton and whole blood agar plates (herein defined as “BT” rats). However, no bacteria were isolated from the 12 normal rats. These results indicate that CCL4-induced cirrhosis increased the incidence of BT.

In addition to the number of bacteria obtained from MLN tissue cultures, we also used LBP, a soluble acute-phase protein that binds to bacterial lipopolysaccharide and elicits immune responses by presenting lipopolysaccharide to cell surface pattern recognition receptors, as an indicator of BT severity. As shown in Fig. 1b, the plasma concentration of LBP was correlated with colony number, with a correlation coefficient as high as 0.918 (P < 0.001). Figure 1c demonstrates that the concentration of LBP was significantly higher in cirrhotic rats with BT than in normal control rats or cirrhotic rats without BT. Furthermore, the concentration of LBP was significantly lower in antibiotic- than placebo-treated cirrhotic rats (4.9 ± 0.8 versus 11.2 ± 5.5; P < 0.05) (Fig. 1d).

To further affirm that BT can result from intestinal bacteria in cirrhosis, 10^9 RFP-marked *E. coli* were administered via gavage to normal and cirrhotic rats, and their organs were then examined using Clairvivo OPT Plus microscopy to track *E. coli* migration. Two hours later, a fluorescent signal was observed in the whole intestinal tract (Fig. 1e), and after 2 and 6 hours, 60% (6/10) of the cirrhotic rats with BT exhibited strong florescence in the MLNs and liver (Fig. 1f). In the lungs, the strongest signal was observed at 6 hours after lavage (Fig. 1f). In the mesentery, the fluorescence signal was strong in the cirrhotic rats with BT but weak in the normal rats (Fig. 1g). The data reveal that the marked bacteria translocated from the gut to the MLNs and into liver, demonstrating a possible pathophysiologial route for the development of infectious complication in advanced cirrhosis.

Cirrhotic rats with BT have worse liver functions, lower body weight, and higher spleen weight and ascites volume than those without BT. As shown in Table 1, the serum levels of Globulin, ALP, AST, and IL10 were significantly higher in cirrhotic rats with BT than in normal rats. The serum levels of ALT, AST and TBil were higher only in cirrhotic rats with BT. However, the serum levels of total protein and albumin and the albumin/globulin ratio was significantly lower in cirrhotic rats with BT than in normal control rats and cirrhotic rats without BT. The concentration of LBP was negatively associated with the albumin/globulin ratio (ρ = −0.769, P < 0.01) and the albumin/globulin ratio (ρ = 0.655, P < 0.05) (Fig. 2a) but was positively associated with the levels of AST (ρ = 0.635, P < 0.05), TBil (ρ = 0.688, P < 0.05), and DBil 0.692 (P < 0.05) (Fig. 2b). Serum levels of albumin and the albumin/globulin ratio were significantly higher and serum levels of ALT, AST, TBil and DBil were significantly lower in the antibiotic-treated cirrhotic rats than in the placebo-treated cirrhotic rats (Table 2). These results indicate that BT at least promotes an increase in serum AST levels and a decrease in serum albumin levels during the processes underlying CCL4-induced cirrhosis.

As shown in Table 1, there were lower final body weights, higher spleen weights and larger ascites volumes in the cirrhotic rats with BT than in the normal rats and/or cirrhotic rats without BT. The concentration of LBP was negatively associated with body weight (ρ = −0.893, P < 0.001) but positively associated with spleen weight (ρ = 0.665; P < 0.05) and the amount of ascites (ρ = 0.878, P < 0.001) (Fig. 2c). Final body weight was significantly higher, while spleen weight and ascites volume were significantly lower, in the antibiotic- than in the placebo-treated cirrhotic rats (Table 2). These results indicate that BT plays important roles in changing these factors.

BT may increase Tregs in the proximal small intestine and decrease Th17 in the whole intestine and blood may in cirrhotic rats. Some of the changes in the percentage of different types of CD4+ T cells in some tissues appear to be associated with BT in liver cirrhotic rats because they were observed in liver cirrhotic rats both with BT and without BT but were not observed in normal rats or cirrhotic rats without BT. These changes included an increase in the percentage of Tregs in the proximal small intestine (Fig. 3a) and a decrease in the percentage of Th17 cells in the proximal and distal small intestine (Fig. 3a and b), caecum (Fig. 3c), colon (Fig. 3d) and blood (Fig. 3f). One possible explanation for this result is that BT cells may specifically induce the development or differentiation of only some types of CD4+ T cells, and another is that specific CCL4-induced alterations in the relative abundance of some CD4+ T cells lead to BT.

To explore the cause and effect relationship between BT and the changes in the proportions of CD4+ T cells that occurred specifically in BT rats, as described above, we investigated the changes that occurred in these cells in rats with liver cirrhosis that were prevented from developing BT by intestinal decontamination, which was ensured using cocktails of antibiotics. As shown in Fig. 1g, gut decontamination resulted in a significantly (P < 0.05) lower concentration of LBP in the antibiotic-treated than in the placebo-treated cirrhotic rats. The percentage of Treg cells in the CD4+ T cell population in the proximal small intestine was lower (Fig. 4a), whereas the proportion of Th17 cells in the proximal and distal small intestine (Fig. 4a and b), caecum (Fig. 4c), colon (Fig. 4d) and blood (Fig. 4f) was higher in the cirrhotic rats with antibiotics than in the cirrhotic rats without antibiotics. However, the percentage of these cells was similar between cirrhotic rats with either placebo or antibiotics. These data indicate that BT causes an increase in the number of Treg cells and the severity of BT in cirrhotic rats with BT. The percentage of Treg cells in the proximal small intestine was positively correlated with the serum concentration of LBP (ρ = 0.691, P < 0.05) (Fig. 5a), further validating the notion that BT causes an increase in the number of Treg cells in the proximal small intestine. The serum concentration of LBP was negatively associated with the percentage of Th17 cells in the proximal small intestine (ρ = −0.836, P < 0.01), the distal small intestine (ρ = −0.861, P < 0.01), and the caecum (ρ = −0.675, P < 0.05) (Fig. 5b), further supporting the hypothesis that BT causes a decrease in the number of Th17 cells in these tissues.
CCl₄-induced cirrhosis causes an increase in Tregs in the liver and a decrease in Th1 cells in the caecum and blood. First, the decrease in Th1 cells in the population of CD4⁺ T cells in the blood occurred only in the liver cirrhotic rats with BT, as mentioned above (Fig. 3f). Moreover, the percentage of Th1 cells in the
CD4+ T cells in the blood of cirrhotic rats with and without antibiotics was significantly lower than the percentage in the normal control rats, but they was no significant difference between the cirrhotic rats with and without antibiotics (Fig. 4f), indicating that the decrease in Th1 cells in the blood of cirrhotic rats was a result of treatment with CCl4 and may be a possible cause of BT. Second, the percentage of Th1 cells in the CD4+ T cells in the caecum was lower in the cirrhotic rats with BT, without BT, with antibiotics and with placebo than in the normal controls, but there was no difference between the rats with BT, without BT, with antibiotics or without antibiotics and their respective normal controls (Fig. 4c). This indicates that the decrease in the number of Th1 cells in the caecum was the result of CCl4-induced cirrhosis and was not affected by BT. Third, the percentage of Tregs in the liver was higher in the cirrhotic rats with BT, without BT, with antibiotics or with placebo than in their respective normal controls. There was a significant difference between the cirrhotic rats with and without BT. This result indicates that the enrichment in Treg cells in the liver may have been caused in large part by the injection of CCl4 and also by BT.

The percentage of Treg cells in the liver was positively correlated with the serum concentration of LBP (r = 0.760, P < 0.05) (Fig. 5a), indicating that Treg cells play an important role in the liver during the induction of BT. There was no significant correlation between the concentration of LBP and the percentage of Th1 cells in the caecum, further confirming that the changes in the number of Th1 cells in the caecum may not be affected by BT.

**BT may aggravate the cirrhosis caused decrease in Th1 cells in the proximal and distal small intestine and liver and increase in Th17 cells in the liver and the number of Tregs in the distal small intestine and colon.** First, neither an increase in the percentage of Tregs in the distal small intestine and colon nor a decrease in the percentage of Th1 cells in the proximal and distal small intestine and liver, both of which appeared to be specific to cirrhotic rats with BT, as mentioned above, were observed between cirrhotic rats treated with antibiotics or placebo. This most likely indicates that BT contributed to the changes observed in these cells and does not exclude the notion that BT is an indicator of the different changes that were observed to be induced in these cells by CCl4. Second, the percentage of Th17 cells in the CD4+ T cell population in the liver was higher in the cirrhotic rats with BT, without BT, with antibiotics or with placebo than in their respective normal controls and also higher in the cirrhotic rats treated with placebo than in the cirrhotic rats treated with antibiotics, indicating that the injections of CCl4 were the main cause of the increase in Th17, while BT was a promotor of this increase.

The serum concentration of LBP was positively correlated with the percentage of Treg cells in the distal small intestine (r = 0.636, P < 0.05) (Fig. 5a), further indicating that BT plays an important role in the increase in Treg cells observed in the distal small intestine. The blood concentration of LBP was also negatively associated with the percentage of Th1 cells in the proximal small intestine (r = −0.809, P < 0.01), the distal small intestine (r = −0.802, P < 0.01) and the liver (r = −0.836, P < 0.05) (Fig. 5c), indicating that the Th1 cells in each of these sites are important for host defences against BT.

Table 1. Characteristics of normal rats and cirrhotic rats with or without BT. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidase; TBIL, total bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin; GGT, gamma-glutamyl transpeptidase. The data are presented as the means ± SD. *P < 0.05, BT versus Normal; **P < 0.05, Without BT versus Normal; ***P < 0.05, BT versus Without BT, one-way ANOVA.

| Indexes | Normal (n = 12) | Without BT (n = 12) | BT (n = 11) |
|---------|----------------|------------------|------------|
| Total protein (g/dL) | 5.1 ± 0.3 | 5.0 ± 1.3 | 4.1 ± 0.6** |
| Albumin (g/dL) | 3.3 ± 0.2 | 2.6 ± 0.9** | 1.5 ± 0.4** |
| Globulin (g/dL) | 1.8 ± 1.5 | 2.5 ± 0.2** | 2.5 ± 0.1* |
| Albumin/Globulin | 1.9 ± 0.1 | 1.0 ± 0.3** | 0.7 ± 0.2* |
| ALT (U/L) | 49.6 ± 13.9 | 154.6 ± 34.6 | 228.3 ± 159.0* |
| AST (U/L) | 76.5 ± 11.2 | 318.9 ± 94.6 | 685.2 ± 670.8* |
| ALP (U/L) | 29 ± 32.6 | 165.7 ± 110.0** | 198.9 ± 113.4* |
| TBIL (μmol/L) | 1.8 ± 0.6 | 21.7 ± 15.1** | 27.2 ± 19.5* |
| DBIL (μmol/L) | 1.8 ± 0.6 | 18.9 ± 12.3** | 24.0 ± 16.3* |
| IBIL (μmol/L) | 0 ± 0.9 | 2.9 ± 3.0 | 3.7 ± 3.4* |
| GGT (U/L) | −2.9 ± 4.1 | 16.3 ± 10.0** | 16.6 ± 14.6* |
| Initial body weight (g) | 212.5 ± 8.1 | 213.0 ± 5.6 | 213.6 ± 7.0 |
| Final body weight (g) | 469.5 ± 11.3 | 379.5 ± 17.1** | 346.2 ± 50.6** |
| Body weight increase (g) | 257.0 ± 10.1 | 166.6 ± 16.0** | 132.6 ± 46.7** |
| Spleen weight (g) | 0.9 ± 0.1 | 1.4 ± 0.3** | 1.7 ± 0.4** |
| Spleen weight/Final body weight (%) | 0.19 | 0.36 | 0.49 |
| Ascites amount (mL) | / | 16.2 ± 7.5 | 25.7 ± 5.4* |
| Ascites/Final body weight (mL/kg) | / | 43.1 ± 20.9 | 76.0 ± 21.0* |
Discussion

The characters and function of CD4+ T cells suggest that they potentially play important roles in the regulation of both BT and liver cirrhosis. On the one hand, CD4+ T cells are critical in the host to combat specific pathogens and to thereby prevent BT and infections, but their development and differentiation depend on the presence of and can adapt in response to microbes, which themselves affect liver cirrhosis. On the other hand, liver diseases, such as liver cirrhosis, may influence liver and gut CD4+ T cells, contributing to an imbalance in intestinal homeostasis and the development of BT. To the best of our knowledge, we are the first to disclose the presence of a major interaction between BT, CD4+ T cells and liver cirrhosis. We used a CCl4-induced rat model to perform this study, and we suggest that this model will be helpful for studies aimed at preventing the development of BT and liver cirrhosis.

Figure 2. BT is associated with liver damage. Correlations between plasma LBP concentrations and albumin concentration and the albumin/globulin ratio (a), AST, TBil, and DBil levels (b), and spleen weight, body weight and the amount of ascites (c) in cirrhotic rats with BT. Spearman's rank test was used.
Th1 cells have an anti-fibrotic effect in the liver27, BT exacerbates liver cirrhosis. Hence, it may also be helpful for bial response in the liver and the proximal and distal small intestine. Because Th17 cells promote fibrosis whereas defense against pathogens, BT may contribute to the weakened cellular but strengthened extracellular antimicro-
capsular polysaccharide, or metabolites, such as short chain fatty acids, via BT22. Simultaneously, the reduction rats. The enrichment of Treg cells observed in the gut may have been induced by bacterial components, such as of Th17 cells in the whole intestine and blood, and that these events are potentially caused by BT in cirrhotic
We found that BT was positively associated with the severity of liver cirrhosis, and we suggest therefore that determining how to breaking the vicious circle between them would be of great clinical significance. Body weights were significantly lower and spleen weights and the volume of ascites were significantly higher in the cirrhotic rats with BT than in those without BT. The concentration of LBP, a marker of BT, was negatively associated with the levels of total protein and albumin but positively correlated with AST, TBil, and DBil levels. Cirrhotic rats treated with antibiotics had levels of liver damage that were similar to those observed in the cirrhotic rats without BT and liver function that was better than that observed in the cirrhotic rats treated with placebo (supplementary Fig. 1). Therefore, our results support the notion that intestinal decontamination with antibiotics or probiotics improves survival, liver function and complications in patients with cirrhosis21.

The mechanism by which BT affects liver cirrhosis is a subject of major concern. On the one hand, we found that there was an increase in the number of Tregs in the proximal small intestine and a decrease in the number of Th17 cells in the whole intestine and blood, and that these events are potentially caused by BT in cirrhotic rats. The enrichment of Treg cells observed in the gut may have been induced by bacterial components, such as capsular polysaccharide, or metabolites, such as short chain fatty acids, via BT22. Simultaneously, the reduction in bacteria in the intestine and the increase in bacteria in the extraintestinal organs that were induced by BT are considered to be major causes of the depletion observed in intestinal Th17 cells. In the absence of pathology, Th17 cells constitute a rare cell population; even though gut associated lymphoid tissue (GALT) is home to nearly 95% of the body’s CD4+ T-cells, including Th17 cells23. Pathogenic infections, such as those caused by extracellular bacteria, may result in a dramatic increase in the number of Th17 cells at the site of infection24. Th17 cells play important roles in the defence against microbes, particularly at mucosal sites, and in sustaining homeostasis in enterocytes. In contrast, Treg cells exert anti-inflammatory functions and control self-reactive T cells, including Th1, Th2, and Th17 cells. As a result, the enrichment of Treg cells and the depletion of Th17 cells in the intestine may cause further damage to intestinal barrier integrity and aggravate BT, thereby potentially leading to fatal complications, such as spontaneous bacterial peritonitis, in liver cirrhosis25. On the other hand, we observed that BT may aggravate the CCl4-induced decrease in Th1 cells in the proximal and distal small intestine and liver and increase in Th17 cells in the liver and Tregs in the distal small intestine and colon. Because Th1 cells are important for cytotoxic immunity to viruses and intracellular pathogens26 and Th17 cells are critical for the mucosal barrier defense against pathogens, BT may contribute to the weakened cellular but strengthened extracellular antimicrobial response in the liver and the proximal and distal small intestine. Because Th17 cells promote fibrosis whereas Th1 cells have an anti-fibrotic effect in the liver27, BT exacerbates liver cirrhosis. Hence, it may also be helpful for alleviating CCl4-mediated inflammation in the distal small intestine and colon, which can be accidentally induced as a result of its contribution to the upregulation of Treg cells.

Another important issue is the underlying cause of BT in liver cirrhosis. In this study, we found that only a decrease in Th1 cells in the blood of cirrhotic rats was largely induced by CCl4 and therefore a potential cause of

| Indexes                        | Placebo (n = 10) | Antibiotics (n = 10) | Placebo (n = 8) | Antibiotics (n = 8) |
|-------------------------------|-----------------|---------------------|----------------|-------------------|
| Total protein (g/dL)          | 4.2 ± 0.8       | 5.0 ± 0.8           | 5.0 ± 0.4      | 5.2 ± 0.2         |
| Albumin (g/dL)                | 1.9 ± 1.0       | 3.0 ± 0.3*          | 3.3 ± 0.2*     | 3.4 ± 0.2         |
| Globulin (g/dL)               | 2.6 ± 0.6       | 2.4 ± 0.3           | 1.8 ± 0.1*     | 1.8 ± 0.2**       |
| Albumin/Globulin              | 0.7 ± 0.3       | 1.3 ± 0.3*          | 1.9 ± 0.1*     | 1.9 ± 0.2**       |
| ALT (U/L)                     | 204.5 ± 94.8    | 112.2 ± 24.6*       | 44.0 ± 14.9*   | 56.4 ± 10.2**     |
| AST (U/L)                     | 546.3 ± 364.5   | 265.7 ± 56.9*       | 70.7 ± 9.7*    | 83.6 ± 9.0**      |
| ALP (U/L)                     | 221.1 ± 132.3   | 109.5 ± 53.8        | 28.3 ± 36.8*   | 30.0 ± 31.1**     |
| GGT (U/L)                     | 24.2 ± 13.4     | 16.2 ± 8.6          | −2.7 ± 1.6*    | −3.2 ± 1.1*       |
| TBIL (μmol/L)                 | 39.3 ± 16.4     | 20.8 ± 10.7*        | 2.0 ± 0.0*     | 1.6 ± 0.9**       |
| DBIL (μmol/L)                 | 33.7 ± 13.9     | 16.5 ± 7.1*         | 2.0 ± 1.3*     | 2.4 ± 0.9**       |
| IBIL (μmol/L)                 | 5.2 ± 3.0       | 2.0 ± 2.6           | −0.3 ± 1.5*    | −0.8 ± 1.1        |
| Initial body weight (g)       | 217.2 ± 4.4     | 213.8 ± 7.3         | 214.2 ± 8.6    | 210.8 ± 8.0       |
| Final body weight (g)         | 377.7 ± 48.5    | 390.0 ± 16.8        | 469.8 ± 10.2*  | 469.2 ± 13.3**    |
| Body weight increase (g)      | 160.5 ± 45.7    | 176.2 ± 15.0        | 255.7 ± 11.4*  | 258.3 ± 9.4**     |
| Spleen weight (g)             | 1.6 ± 0.3       | 1.3 ± 0.3*          | 0.9 ± 0.1*     | 0.9 ± 0.0**       |
| Spleen weight/Initial weight  | 4.4 ± 1.0       | 3.2 ± 0.6*          | 1.8 ± 0.1*     | 1.9 ± 0.1**       |
| Ascites amount (mL)           | 24.3 ± 3.4      | 8.5 ± 2.3*          | /              | /                 |
| Ascites/Body weight (mL/kg)   | 64.6 ± 7.2      | 23.4 ± 6.0*         | /              | /                 |

Table 2. Characteristics of Placebo- and Antibiotic-Treated Cirrhotic and Control Rats. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidase; TBIL, total bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin. The data are presented as the means ± standard deviation. *P < 0.05, placebo-treated normal rats versus placebo-treated cirrhotic rats; **P < 0.05, antibiotics-treated normal rats versus antibiotics-treated cirrhotic rats; "P < 0.05, antibiotics- versus placebo-treated cirrhotic rats. The unpaired Student’s t test with Bonferroni’s correction was used.
BT. However, there was no significant correlation between the percentage of Th1 cells and the level of LBP in the blood of cirrhotic rats, indicating that even if the decrease in Th1 cells in the blood of cirrhotic rats contributed to BT, it was not a major factor. Consequently, alterations in CD4+ T cells were not observed to induce BT in rats with CCl4-induced liver cirrhosis. The destruction of components of the mucosal barrier, such as the mucus layer, the glycocalyx or a layer of epithelial cells, may be the first step to inducing BT during liver cirrhosis.

In conclusion, we found that BT may cause an increase in the number of Treg cells in the proximal small intestine and a decrease in the number of Th17 cells in the whole intestine and blood in cirrhotic rats. It may also aggravate the CCl4-induced decrease in the number of Th1 cells in the proximal and distal small intestine, liver, caecum, and blood and the CCl4-induced increase in the number of Th17 cells in the liver and in the number of Tregs in the distal small intestine, colon, and liver. The results of this study may be helpful for further research into treatments for liver cirrhosis.

Methods
All experimental procedures were conducted according to the 2011 National Institutes of Health Guide for the care and use of laboratory animals. The study was approved by the ethics committee of the First Affiliated Hospital, College of Medicine, Zhejiang University. All experimental animals received humane care.

CCl4-induced liver cirrhosis. Cirrhosis was induced in male pathogen-free Sprague–Dawley rats (200–230 g initial weight) via the subcutaneous injection of a 50% (v/v) CCl4 solution in olive oil (Sigma-Aldrich, St. Louis, MO) into the dorsal region twice per week at a dose of 2 mL/kg. The dose was administered at the same time as 0.35 g/L Phenobarbital (Sigma-Aldrich) in the rats’ drinking water. In the control rats, CCl4 was replaced with olive oil. After 12–16 weeks, some of the rats had developed ascites, and in these cases, CCl4 and phenobarbital administration were continued for 2 weeks after the onset of ascites. The administration of phenobarbital and CCl4 was stopped 1 week before the experiments were performed.
**Study design.** Out of the 80 rats that were treated with CCl₄, 53 developed cirrhosis and ascites. This study consisted of 3 experiments. In protocol 1, we monitored the occurrence of BT in the intestinal bacteria in cirrhosis. Out of the 80 rats that were treated with CCl₄, 53 developed cirrhosis and ascites. This study consisted of 3 experiments. In protocol 1, we monitored the occurrence of BT in the intestinal bacteria in cirrhosis. In these rats, a total of 10⁸ RFP-marked *E. coli* were administered via gavage to 10 rats with cirrhosis and ascites and 6 healthy, phenobarbital-treated age- and sex-matched rats. In protocol 2, we determined the distribution of Treg, Th17, and Th1 cells in the entire intestinal lamina propria, liver, and blood and evaluated their potential relationships with BT. In these experiments, we used 23 rats with cirrhosis and ascites in addition to 12 controls. In protocol 3, we investigated the effects of bowel bacterial decontamination on the distribution of Treg, Th17 and Th1 cells in 20 rats with cirrhosis and 16 control rats. To achieve this aim, after ascites onset, the animals were randomized in two groups that receive either broad-spectrum non-absorbable antibiotics, norfloxacin (10 mg/kg/day; Sigma-Aldrich) and vancomycin (16 mg/day; Sigma-Aldrich) or a placebo dissolved in drinking water. The treatments were administered orally for 2 weeks.

**Bacterial translocation assessment.** A 10–15 mL volume of blood was obtained from each rat via puncture in the vena cava inferior. The MLNs of the ileocaecal area were aseptically isolated. After the isolates were ground, 10μL of homogenized MLNs were cultured on MacConkey (Thermo Fisher Scientific, Waltham, MA), Mueller–Hinton (Thermo Fisher Scientific), and whole blood agar (Bio Merieux, Lyon, France) for 48 hours at 37°C. BT was defined as the presence of viable organisms in the MLN culture. To determine whether bacteriaemia was present, 3 mL of blood was drawn from the inferior vena cava and inoculated into aerobic and anaerobic Bactec culture bottles. The cultures were incubated at 35°C, and the growth value (a measurement of CO₂ production by the bacteria) was continuously monitored for at least 7 days. For BT monitoring, 10 cirrhotic rats and four control rats were lavaged with 10⁸ RFP-marked *E. coli*. The small intestine, colon, heart, lung, spleen, MLNs, kidneys, and liver were collected at 2 or 6 hours after lavage. The organs were rinsed in ice-cold PBS twice, and the RFP signal was visualised using a Clairvivo OPT Plus fluorescence microscope (Shimadzu Corporation, Kyoto, Japan) at a wavelength of 583 nm.
Immune cell isolation. Peripheral blood mononuclear cells (PBMCs) were prepared from venous blood using density gradient centrifugation. Intrahepatic lymphocytes were isolated as previously described, with some modifications. Briefly, the intestine was removed and placed in ice-cold PBS supplemented with 5% heat-inactivated FCS. After the residual mesenteric fat was removed, the Peyer’s patches were carefully excised, and the intestine was opened longitudinally. The intestine was then thoroughly washed in ice-cold PBS and cut into 1.0-cm pieces. The pieces were incubated twice in 30 mL of 5 mM EDTA (Sigma-Aldrich) in RPMI media supplemented with 5% heat-inactivated FCS for 20 min at 37°C with slow rotation. After each incubation, fresh EDTA (Sigma-Aldrich) was added, and the intraepithelial lymphocytes (IELs) in the epithelial cell layer were removed via filtration through a 100-μm filter (BD Pharmingen, Franklin Lakes, USA). After the second EDTA incubation, the pieces were washed in PBS, cut into 1-mm² pieces using a razor blade, and placed in 25 mL of digestion solution containing 5% FCS, 0.65 mg/mL collagenase VIII, and 1 unit/mL of DNase I. During digestion, the pieces were incubated at 37°C for 20 min with slow rotation. After 20 min, the solution was strongly vortexed and then passed through a 100-μm filter (BD Pharmeden). The supernatants were then combined, washed twice with 5% heat-inactivated FCS and suspended in 10 mL of a 40% fraction of Percoll gradient. The suspension was overlaid on 5 mL of the 80% fraction in a 15-mL Falcon tube (BD Pharmeden). Percoll gradient separation was performed using centrifugation for 20 min at 2500 rpm at room temperature. Lamina propria lymphocytes (LPLs) were collected in the interphase of the Percoll gradient, washed once, and resuspended in PBS supplemented with 0.3% (w/v) BSA and 0.09% (w/v) sodium azide. Isolated cells were used immediately for experiments.

Figure 5. BT is associated with changes in the cellular immunity response. (a) Correlations between the concentration of LBP and the percentage of Treg cells in the proximal small intestine, distal small intestine, and liver. (b) The correlation between the concentration of LBP and the percentage of Th17 cells in the proximal small intestine, distal small intestine, and caecum. (c) The correlation between the concentration of LBP and the percentage of Th1 cells in the proximal small intestine, distal small intestine, and liver. Spearman’s rank test was used.
Surface and intracellular cytokine staining. Collected cells (1 x 10⁶ cells/mL) were suspended in staining buffer and stained for surface expression of CD3, CD4, and CD25. After surface staining, the cells were resuspended in Fixation/Permeabilization solution (BD Cytofix/Cytoperm kit, BD Pharmingen), and stained for intracellular Foxp3 expression according to the manufacturer’s protocol. To detect IFN-γ and IL-17A, lymphocytes (1 x 10⁶/mL) were stimulated for 5 hours with 2 μL Leukocyte Activation Cocktail with BD GolgiPlug™ (BD Pharmingen) in a cell culture incubator at 37 °C. The cells were stained for surface CD3 and CD4 expression and then fixed and permeabilized using a BD Cytofix/Cytoperm kit. The cells were then stained for intracellular IFN-γ and IL-17A. Cytokines were analysed using flow cytometry on a BD LSR II flow cytometer (BD Pharmingen), and the resulting data were analysed using FlowJo software (Treestar, Ashland, OR). The following antibodies were used: PE- or FITC-labelled anti-CD3 (G4.18, BD Pharmingen), PE- or FITC-labelled anti-CD25 (OX-39, BD Pharmingen), APC-labelled anti-CD4 (OX-35, BD Pharmingen), PerCP-labelled anti-CD8a (OX-8, BD Pharmingen), PE-Cyanine7-labelled anti-Foxp3 Ab (FJK-16s, eBioscience, San Diego, CA), PE-labelled anti-IFN-γ (DB-1, BD Pharmingen), and Alexa Fluor488-labelled anti-IL-17A (eBiol17B7, eBioscience).

Measurement of liver function. The serum concentrations of total protein (TP), albumin (Alb), globulin (Glb), alanine aminotransferase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), and gamma-glutamyl transpeptidase (GGT) and total bilirubin (TBil), direct bilirubin (DBil), and indirect bilirubin (IBil) levels were measured using a standard clinical automated analyser (SRL, Tokyo, Japan).

Lipopolysaccharide-binding protein ELISA. Blood samples were collected into endotoxin-free tubes (Endo Tube ET; Chromogenix AB, Sweden). After the samples were centrifuged, the blood plasma was stored at −80 °C. Plasma LBP levels were measured using an enzyme-linked immunosorbent assay (ELISA) kit (Cell Sciences, Newburyport, MA) according to the manufacturer’s instructions.

Statistical analysis. The results are shown as the mean ± standard deviation. The normality of the distribution of the variables was evaluated using the Kolmogorov-Smirnov test. For multiple comparisons, differences among groups were determined using one-way ANOVA and the unpaired Student’s t test with Bonferroni’s correction. Spearman’s rank correlation was used to determine correlations between variables. Statistical significance was set at 0.05. All statistical analyses were performed using SPSS 19.0 for Windows (SPSS, Inc., Chicago, USA).

References
1. Berg, R. D. & Garlington, A. W. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infect. Immun. 23, 403–411 (1979).
2. Wiest, R. & Garcia-Tsao, G. Bacterial translocation (BT) in cirrhosis. Hepatology. 41, 422–433 (2005).
3. Garcia-Tsao, G. & Wiest, R. Gut microbiota in the pathogenesis of the complications of cirrhosis. Best Pract. Res. Clin. Gastroenterol. 18, 353–372 (2004).
4. De Minicis, S. et al. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology. 59, 1738–1749 (2014).
5. Fuku, H. Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia. World J. Hepatol. 7, 425–442 (2015).
6. Bellot, P., Frances, R. & Such, J. Pathological bacterial translocation in cirrhosis: Pathophysiology, diagnosis and clinical implications. Liver Int. 33, 31–39 (2013).
7. Brenchley, J. M. & Douek, D. C. Microbial translocation across the GI tract. Annu. Rev. Immunol. 30, 149–173 (2012).
8. Wiest, R., Lawson, M. & Geuking, M. Pathological bacterial translocation in liver cirrhosis. J. Hepatol. 60, 197–209 (2014).
9. Kamada, N., Seo, S. U., Chen, G. Y. & Nunez, G. Role of the gut microbiota in immunity and inflammatory disease. Nat. Rev. Immunol. 13, 321–335 (2013).
10. Ivanov, I. I. et al. The orphan nuclear receptor RORgammaT directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 126, 1121–1133 (2006).
11. Chevalier, M. F. et al. The Il17/Il17f ratio, IL-1RA and sCD14 levels in primary HIV infection predict the T-cell activation set point in the absence of systemic microbial translocation. PLoS Pathog. 9, e1003453 (2013).
12. Arakawa, K. et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science. 331, 337–341 (2011).
13. Jonuleit, H. et al. Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J. Exp. Med. 196, 255–260 (2002).
14. Wang, S. et al. MyD88 adaptor-dependent microbial sensing by regulatory T cells promotes mucosal tolerance and enforces commensalism. Immunity. 43, 289–303 (2015).
15. Alibol, A. et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology. 37, 208–217 (2003).
16. Alibol, A., de-la-Hera, A. & Alvarez-Mon, M. Serum lipopolysaccharide-binding protein prediction of severe bacterial infection in cirrhotic patients with ascites. Lancet. 363, 1608–1610 (2004).
17. Alibol, A. et al. Tumour necrosis factor-alpha expression by activated monocytes and altered T-cell homeostasis in ascitic alcoholic cirrhosis: Amelioration with norfloxacin. J. Hepatol. 40, 624–631 (2004).
18. Su, T. H., Kao, J. H. & Liu, C. J. Molecular mechanism and treatment of viral hepatitis-related liver fibrosis. Int. J. Mol. Sci. 15, 10578–10604 (2014).
19. Alibol, A., Lario, M. & Alvarez-Mon, M. Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance. J. Hepatol. 61, 1385–1396 (2014).
20. Jalan, R. et al. Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013. J. Hepatol. 60, 1310–1324 (2014).
21. Fernandez, J. et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 133, 818–824 (2007).
22. Kabat, A. M., Pott, J. & Maloy, K. J. The mucosal immune system and its regulation by autopaghy. Front. Immunol. 7, 240 (2016).
23. Espuangles, E. et al. Control of TH17 cells occurs in the small intestine. Nature. 475, 514–518 (2011).
24. Ishigame, H. et al. Differential roles of interleukin-17A and -17F in host defense against mucocutaneous bacterial infection and allergic responses. Immunity. 30, 108–119 (2009).
25. Lutz, P., Nischalke, H. D., Strasburg, C. P. & Spengler, U. Spontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liver. World J. Hepatol. 7, 304–314 (2015).
26. Winstead, C. J. Follicular helper T cell-mediated mucosal barrier maintenance. Immunol. Lett. 162, 39–47 (2014).
27. Pellicoro, A., Ramachandran, P., Iredale, J. P. & Fallowfield, J. A. Liver fibrosis and repair: Immune regulation of wound healing in a solid organ. Nat. Rev. Immunol. 14, 181–194 (2014).

28. Quigley, E. M. Leaky gut - concept or clinical entity? Curr. Opin. Gastroenterol. 32, 74–79 (2016).

29. Teltschik, Z. et al. Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense. Hepatology. 55, 1154–1163 (2012).

30. Munoz, L. et al. Interaction between intestinal dendritic cells and bacteria translocated from the gut in rats with cirrhosis. Hepatology. 56, 1861–1869 (2012).

31. Munoz, L. et al. Mesenteric Th1 polarization and monocyte TNF-alpha production: First steps to systemic inflammation in rats with cirrhosis. Hepatology. 42, 411–419 (2005).

32. Morsy, M. A. et al. Isolation, purification and flow cytometric analysis of human intrahepatic lymphocytes using an improved technique. Lab. Invest. 85, 285–296 (2005).

Acknowledgements
The authors thank Dr. Yue Wang for helping with the data analysis and presentation and Zhihua Liu for providing the red fluorescent protein-tagged E. coli. This study was supported by the Key Program (No. 81330011) of the National Science Foundation of China (NSFC), the National Basic Research Program of China (973 program) (No. 2013CB531401), the National High-technology R&D Program of China (No. 2013CB531406), the general programme (81570512) of the NSFC, and the Fundamental Research Funds for the Central Universities.

Author Contributions
L.J.L., H.Y.S. and L.X.L. conceived the project. H.Y.S., H.F.L., H.Y.J. and N.Z. performed the experiments. H.C.C., J.Z.Y., H.Y.J., H.H.D., X.J.H., W.Y., X.W.J. and B.W.Z. contributed to discussions regarding the project. H.Y.S., L.X.L., H.C.C. and L.J.L. analysed the data and wrote and revised the manuscript.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Shi, H. et al. Bacterial translocation aggravates CCl4-induced liver cirrhosis by regulating CD4+ T cells in rats. Sci. Rep. 6, 40516; doi: 10.1038/srep40516 (2016).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2017